Skip to main content

Advertisement

SpringerLink
Log in

Obesity’s role in secondary male hypogonadism: a review of pathophysiology and management issues

  • Medicine
  • Published:
SN Comprehensive Clinical Medicine Aims and scope Submit manuscript

Abstract

Obesity and male hypogonadism are both associated with one another. Moreover, male hypogonadism can serve as a risk factor for obesity while obesity can serve as a risk factor for male hypogonadism. There has been little research regarding obesity and its reduction on that of gonadal function. Lifestyle factors as well as other factors have been attributed to the development of obesity which can induce gonadal dysfunction. Therefore, the treatment of male hypogonadism is of great interest for both providers and patients. The future of hypogonadism therapy may exist with the development of aromatase inhibitors that can minimize undesired effects and allow the benefits of androgens. Testosterone treatment can lead to compromised fertility and addiction. Aromatase allows for the peripheral conversion of androgens into estrogens resulting in the inhibition of gonadotropin production. Therefore, aromatase inhibitors can be used instead to increase gonadotropin secretion. There is growing evidence that aromatase inhibitors can improve the fertility and raise testosterone levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The role of androgens and estrogens on healthy aging and longevity. J Gerontol Ser A Biol Med Sci. 2012;67(11):1140–52.

    Article  CAS  Google Scholar 

  2. Ullah MI, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014;8:101–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. Rev Urol. 2003;5(4):216–26.

    PubMed  PubMed Central  Google Scholar 

  4. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ. 2005;83(9):700–6.

    PubMed  PubMed Central  Google Scholar 

  5. Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012;14(2):187–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hackett G. Commentary on “Late-onset hypogonadism - beyond testosterone”. Asian J Androl. 2015;17(2):334.

    Article  PubMed  Google Scholar 

  8. Mammi C, Calanchini M, Antelmi A, Cinti F, Rosano GMC, Lenzi A, et al. Androgens and adipose tissue in males: a complex and reciprocal interplay. Int J Endocrinol. 2012;2012:789653.

    Article  PubMed  Google Scholar 

  9. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol. 2007;52(1):54–70.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64(6):682–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol. 2012;2012:625434.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Stanworth RD, Jones TH. Testosterone for the aging male; current evidence and recommended practice. Clin Interv Aging. 2008;3(1):25–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl. 2012;14(3):428–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bain J. The many faces of testosterone. Clin Interv Aging. 2007;2(4):567–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics. 2013;68(Suppl 1):81–8.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hackett G, Kirby M, Sinclair AJ. Testosterone deficiency, cardiac health, and older men. Int J Endocrinol. 2014;2014:143763.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. Rev Urol. 2003;5(Suppl 1):S3–S10.

    PubMed  PubMed Central  Google Scholar 

  18. Bekaert M, Van Nieuwenhove Y, Calders P, Cuvelier CA, Batens A-H, Kaufman J-M, et al. Determinants of testosterone levels in human male obesity. Endocrine. 2015;50(1):202–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gooren LJ. Androgens and male aging: current evidence of safety and efficacy. Asian J Androl. 2010;12(2):136–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Roselli CE, Liu M, Hurn PD. Brain aromatization: classical roles and new perspectives. Semin Reprod Med. 2009;27(3):207–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Shozu M, Fukami M, Ogata T. Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis. Expert Rev Endocrinol Metab. 2014;9(4):397–409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Merlotti D, Gennari L, Stolakis K, Nuti R. Aromatase activity and bone loss in men. J Osteoporos. 2011;2011:230671.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Garringer JA, Niyonkuru C, McCullough EH, Loucks T, Dixon CE, Conley YP, et al. Impact of aromatase genetic variation on hormone levels and global outcome after severe TBI. J Neurotrauma. 2013;30(16):1415–25.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Snyder PJ. Clinical features and diagnosis of male hypogonadism. UpToDate [online serial]. Waltham: UpToDate; 2013.

    Google Scholar 

  25. Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res. 2010;1(3):297–301.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sabanegh E Jr, Agarwal A. “Male Infertility.” Campbell-Walsh Urology. 10th ed. Philadelphia: Saunders Elsevier; 2012. p. 616–47. Print

  27. Snyder, P. J., Matsumoto, A. M., Kirkland, J. L., & Martin, K. A. (2010). Causes of secondary hypogonadism in males. Up to Date. UpToDate, Waltham, MA

  28. Mittre Herve MH, Kottler ML, Pura M. Human gene mutations. Gene symbol: CYP19. Disease: aromatase deficiency. Hum Genet. 2004;114(2):224.

  29. Bouillon R, Bex M, Vanderschueren D, Boonen S. Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab. 2004;89(12):6025–9.

    Article  CAS  PubMed  Google Scholar 

  30. Lanfranco F, Zirilli L, Baldi M, Pignatti E, Corneli G, Ghigo E, et al. A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. Bone. 2008;43(3):628–35.

    Article  CAS  PubMed  Google Scholar 

  31. Deladoey J, Fluck C, Bex M, Yoshimura N, Harada N, Mullis PE. Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab. 1999;84(11):4050–4.

    CAS  PubMed  Google Scholar 

  32. Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab. 1998;83(4):1348–57.

    CAS  PubMed  Google Scholar 

  33. Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med. 2003;348(19):1855–65.

    Article  CAS  PubMed  Google Scholar 

  34. de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.

    Article  CAS  PubMed  Google Scholar 

  37. Fui MNT, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014;16(2):223–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Spitzer WO, Buist AS. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990;45(8):645–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337(2):91–5.

    Article  CAS  PubMed  Google Scholar 

  40. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab. 2004;89(1):61–70.

    Article  CAS  PubMed  Google Scholar 

  41. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689–98.

    CAS  PubMed  Google Scholar 

  42. Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab. 2002;87(12):5476–84.

    Article  CAS  PubMed  Google Scholar 

  43. Atlantis E, Martin SA, Haren MT, O’Loughlin PD, Taylor AW, Anand-Ivell R, et al. Demographic, physical and lifestyle factors associated with androgen status: the Florey Adelaide Male Ageing Study (FAMAS). Clin Endocrinol. 2009;71(2):261–72.

    Article  CAS  Google Scholar 

  44. Haring R, Ittermann T, Volzke H, Krebs A, Zygmunt M, Felix SB, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male. 2010;13(4):247–57.

    Article  CAS  PubMed  Google Scholar 

  45. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab. 2008;93(7):2737–45.

    Article  CAS  PubMed  Google Scholar 

  46. Vodo S, Bechi N, Petroni A, Muscoli C, Aloisi AM. Testosterone-induced effects on lipids and inflammation. Mediat Inflamm. 2013;2013:183041.

    Article  CAS  Google Scholar 

  47. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–5.

    Article  CAS  PubMed  Google Scholar 

  48. Zhao J, Zhai L, Liu Z, Wu S, Xu L. Leptin level and oxidative stress contribute to obesity-induced low testosterone in murine testicular tissue. Oxidative Med Cell Longev. 2014;2014:190945.

    Google Scholar 

  49. Martin RM, Lin CJ, Nishi MY, Billerbeck AE, Latronico AC, Russell DW, et al. Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings. J Clin Endocrinol Metab. 2003;88(7):3027–34.

    Article  CAS  PubMed  Google Scholar 

  50. Binder G, Iliev DI, Dufke A, Wabitsch M, Schweizer R, Ranke MB, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab. 2005;90(1):484–92.

    Article  CAS  PubMed  Google Scholar 

  51. Wit JM, Hero M, Nunez SB. Aromatase inhibitors in pediatrics. Nat Rev Endocrinol. 2011;8(3):135–47.

    Article  CAS  PubMed  Google Scholar 

  52. Henry NL, Giles JT, Stearns V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park, NY). 2008(22, 12):1401–8.

  53. de Ronde W. Therapeutic uses of aromatase inhibitors in men. Curr Opin Endocrinol Diabetes Obes. 2007;14(3):235–40.

    Article  PubMed  Google Scholar 

  54. Bradley KL, Tyldesley S, Speers CH, Woods R, Villa D. Contemporary systemic therapy for male breast cancer. Clin Breast Cancer. 2014;14(1):31–9.

    Article  CAS  PubMed  Google Scholar 

  55. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol. 2005;63(4):381–94.

    Article  CAS  Google Scholar 

  56. Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157(10):681–91.

    Article  PubMed  Google Scholar 

  57. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a metaanalysis. J Urol. 2000;164(2):371–5.

    Article  CAS  PubMed  Google Scholar 

  58. Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  59. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245–84.

    Article  CAS  PubMed  Google Scholar 

  60. Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65(1):99–112.

    Article  CAS  PubMed  Google Scholar 

  61. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–98.

    Article  CAS  PubMed  Google Scholar 

  62. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63(3):280–93.

    Article  CAS  Google Scholar 

  63. Morley JE, Kaiser FE, Sih R, Hajjar R, Perry HM 3rd. Testosterone and frailty. Clin Geriatr Med. 1997;13(4):685–95.

    Article  CAS  PubMed  Google Scholar 

  64. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20(4):378–87.

    Article  CAS  PubMed  Google Scholar 

  65. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82(8):2386–90.

    Article  CAS  PubMed  Google Scholar 

  66. Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl. 2006;29(3):381–91.

    Article  CAS  PubMed  Google Scholar 

  67. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galvan R. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male. 2008;11(3):140–5.

    Article  CAS  PubMed  Google Scholar 

  68. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966–72.

    CAS  PubMed  Google Scholar 

  69. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503–10.

    Article  CAS  PubMed  Google Scholar 

  70. Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes. 2013;3(3-4):73–83.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology. 2014;83(1):167–73.

    Article  PubMed  Google Scholar 

  72. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3):1502–10.

    Article  CAS  PubMed  Google Scholar 

  73. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–27.

    Article  CAS  PubMed  Google Scholar 

  74. Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):224–32.

    Article  CAS  PubMed  Google Scholar 

  75. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–7.

    Article  PubMed  Google Scholar 

  76. Münzer T, Harman SM, Hees P, Shapiro E, Christmas C, Bellantoni MF, et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab. 2001;86(8):3604–10.

  77. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–33.

    Article  CAS  PubMed  Google Scholar 

  78. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Marin P, Arver S. Androgens and abdominal obesity. Bailliere Clin Endocrinol Metab. 1998;12(3):441–51.

    Article  CAS  Google Scholar 

  80. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, et al. Androgen treatment of abdominally obese men. Obes Res. 1993;1(4):245–51.

    Article  CAS  PubMed  Google Scholar 

  81. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol. 2010;73(5):602–12.

    Article  CAS  Google Scholar 

  82. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.

    Article  CAS  PubMed  Google Scholar 

  83. Agledahl I, Hansen JB, Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest. 2008;68(7):641–8.

    Article  CAS  PubMed  Google Scholar 

  84. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007;92(11):4254–9.

    Article  CAS  PubMed  Google Scholar 

  85. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495–503.

    Article  CAS  PubMed  Google Scholar 

  86. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6 Pt 1):528–40.

    Article  CAS  PubMed  Google Scholar 

  87. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.

    Article  CAS  PubMed  Google Scholar 

  88. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.

    Article  PubMed  Google Scholar 

  90. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol. 1994;40(3):341–9.

    Article  CAS  Google Scholar 

  91. Hassan J, Barkin J. Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy. Can J Urol. 2016;23(Suppl 1):20–30.

    PubMed  Google Scholar 

  92. Lippi G, Franchini M, Banfi G. Biochemistry and physiology of anabolic androgenic steroids doping. Mini-Rev Med Chem. 2011;11(5):362–73.

    Article  CAS  PubMed  Google Scholar 

  93. George AJ. The actions and side effects of anabolic steroids in sport and social abuse. Andrologie. 2003;13(4):354–66.

    Article  Google Scholar 

  94. Brower KJ, Blow FC, Young JP, Hill EM. Symptoms and correlates of anabolic-androgenic steroid dependence. Br J Addict. 1991;86(6):759–68.

    Article  CAS  PubMed  Google Scholar 

  95. Boonchaya-anant P, Laichuthai N, Suwannasrisuk P, Houngngam N, Udomsawaengsup S, Snabboon T. Changes in Testosterone Levels and Sex Hormone-Binding Globulin Levels in Extremely Obese Men after Bariatric Surgery. Int J Endocrinol. 2016;2016:1–5.

    Article  CAS  Google Scholar 

  96. Chughtai B, Jarvis TR, Kaplan SA. Testosterone and benign prostatic hyperplasia. Asian J Androl. 2015;17(2):212.

    Article  CAS  PubMed  Google Scholar 

  97. Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Testosterone and Cardiovascular Disease. J Am Coll Cardiol. 2016;67(5):545–57.

    Article  CAS  PubMed  Google Scholar 

  98. Jones SD, Dukovac T, Sangkum P, Yafi FA, Hellstrom WJG. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Sex Med Rev. 2015;3(2):101–12.

    Article  PubMed  Google Scholar 

  99. Ghanim H, Dhindsa S, Abuaysheh S, Batra M, Kuhadiya ND, Makdissi A, et al. Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone. Eur J Endocrinol. 2018;178(3):277–83.

    Article  CAS  PubMed  Google Scholar 

  100. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism. JAMA. 2006;296(19):2351.

    Article  CAS  PubMed  Google Scholar 

  101. Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middleaged men. Prostate. 1993;23(2):99–106.

    Article  PubMed  Google Scholar 

  102. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. Urology. 2000;55(3):397–402.

    Article  CAS  PubMed  Google Scholar 

  103. Ko YH, Moon DG, Moon KH. Testosterone Replacement Alone for Testosterone Deficiency Syndrome Improves Moderate Lower Urinary Tract Symptoms: One Year Follow-Up. World J Men's Health. 2013;31(1):47.

    Article  Google Scholar 

  104. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2010;14(1):53–8.

    Article  PubMed  Google Scholar 

  105. Hamilton A, Volm M. Nonsteroidal and Steroidal Aromatase Inhibitors in Breast Cancer: Page 2 of 3. Oncology. 2001;15(8).

  106. Lombardi P. Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2002;1587(2-3):326–37.

    Article  CAS  Google Scholar 

  107. Geisler J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole–of clinical importance? Br J Cancer. 2011;104(7):1059.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are thankful to Drs. Inefta Reid, Kelly Warren, Todd Miller, and Peter Brink for departmental support, as well as Mrs. Wendy Isser and Ms. Grace Garey for literature retrieval.

Author information

Authors and Affiliations

  1. Department of Physiology and Biophysics, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA

    Omar Seyam, Jason Gandhi & Sardar Ali Khan

  2. Medical Student Research Institute, St. George’s University School of Medicine, West Indies, Grenada

    Jason Gandhi

  3. Department of Internal Medicine, Stony Brook Southampton Hospital, Southampton, NY, USA

    Gunjan Joshi

  4. Foley Plaza Medical, New York, NY, USA

    Noel L. Smith

  5. Department of Urology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA

    Sardar Ali Khan

Authors
  1. Omar Seyam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gunjan Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noel L. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sardar Ali Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sardar Ali Khan.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seyam, O., Gandhi, J., Joshi, G. et al. Obesity’s role in secondary male hypogonadism: a review of pathophysiology and management issues. SN Compr. Clin. Med. 1, 408–418 (2019). https://doi.org/10.1007/s42399-019-00056-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42399-019-00056-7

Keywords

Search

Navigation